Annals of Neurology · 2007 · 919 citations · 33 references
MedicineNeurologyNeuroscienceDementiaImmunopathologyNeurodegenerationAlzheimer DiseaseImmunohistochemistryNeurodegenerative DiseasesNeurodegenerative DisordersNeuropathology Of DementiaTau PathologyAlzheimer Disease Tau PathologyAntibodiesDouble ImmunostainingMicroscopyTar Dna-binding Protein 43 PathologyTdp-43 PathologyUltrastructural Pathology
It is unclear whether TDP‑43 pathology in Alzheimer’s disease reflects concomitant FTLD‑U or merely co‑localization of abnormal proteins. The study sought to quantify FTLD‑U frequency in hippocampal sclerosis and Alzheimer’s disease via TDP‑43 immunohistochemistry. They screened 21 hippocampal sclerosis and 74 Alzheimer’s disease cases for FTLD‑U with TDP‑43 staining, confirmed findings in 93 additional AD cases, and assessed antibody specificity by confocal, electron microscopy, and biochemistry. TDP‑43 immunoreactivity was detected in 71 % of hippocampal sclerosis and 23 % of Alzheimer’s disease cases, with inclusions distinct from tau tangles and associated with granular/filamentous cytosolic material; a higher‑molecular‑weight band appeared in TDP‑43‑positive AD cases, indicating that up to 20 % of AD and over 70 % of hippocampal sclerosis cases show FTLD‑U–like pathology. Published in Annals of Neurology, 2007;61:435–445.
Abstract Objective This study aimed to determine the frequency of frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD‐U) in the setting of hippocampal sclerosis (HpScl) and Alzheimer's disease (AD) using immunohistochemistry for TAR DNA binding protein 43 (TDP‐43), a putative marker for FTLD‐U. Methods Initially, 21 cases of HpScl associated with a variety of other pathological processes and 74 cases of AD were screened for FTLD‐U with TDP‐43 immunohistochemistry. A confirmation study was performed on 93 additional AD cases. Specificity of TDP‐43 antibodies was assessed using double‐immunolabeling confocal microscopy, immunoelectron microscopy, and biochemistry. Results TDP‐43 immunoreactivity was detected in 71% of HpScl and 23% of AD cases. Double immunostaining of AD cases for TDP‐43 and phospho‐tau showed that the TDP‐43–immunoreactive inclusions were usually distinct from neurofibrillary tangles. At the ultrastructural level, TDP‐43 immunoreactivity in AD was associated with granular and filamentous cytosolic material and only occasionally associated with tau filaments. Western blots of AD cases showed a band that migrated at a higher molecular weight than normal TDP‐43 that was not present in AD cases without TDP‐43 immunoreactivity. Interpretation These results suggest that as many as 20% of AD cases and more than 70% of HpScl cases have pathology similar to that found in FTLD‐U. Whether this represents concomitant FTLD‐U or is analogous to colocalization of α‐synuclein and tau in AD, reflecting a propensity for codeposition of abnormal protein conformers, remains to be determined. Ann Neurol 2007;61:435–445
33
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Manuela Neumann, Deepak M. Sampathu, Linda K. Kwong et al. · Science · 2006 · 6.6K citations
Tetsuaki Arai, Masato Hasegawa, Haruhiko Akiyama et al. · Biochemical and Biophysical Research Communications · 2006 · 2.8K citations
Alzheimer Disease in the US Population
Liesi E. Hebert, Paul A. Scherr, Julia L. Bienias et al. · Archives of Neurology · 2003 · 2.2K citations
Medicine, Geriatric Medicine, Population Health Sciences +17
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
Karen S. SantaCruz, Jada Lewis, Jennifer Paulson et al. · Science · 2005 · 2K citations · Full text